.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,910,589

« Back to Dashboard

Details for Patent: 7,910,589

Title:Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Abstract: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.
Inventor(s): Bando; Takuji (Tokushima, JP), Aoki; Satoshi (Naruto, JP), Kawasaki; Junichi (Tokushima, JP), Ishigami; Makoto (Tokushima, JP), Taniguchi; Youichi (Tokushima, JP), Yabuuchi; Tsuyoshi (Tokushima, JP), Fujimoto; Kiyoshi (Naruto, JP), Nishioka; Yoshihiro (Tokushima, JP), Kobayashi; Noriyuki (Tokushima, JP), Fujimura; Tsutomu (Naruto, JP), Takahashi; Masanori (Tokushima, JP), Abe; Kaoru (Tokushima, JP), Nakagawa; Tomonori (Tokushima, JP), Shinhama; Koichi (Tokushima, JP), Utsumi; Naoto (Naruto, JP), Tominaga; Michiaki (Tokushima, JP), Ooi; Yoshihiro (Tokushima, JP), Yamada; Shohei (Tokushima, JP), Tomikawa; Kenji (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Filing Date:Apr 26, 2007
Application Number:11/790,606
Claims:1. Anhydrous Aripiprazole Crystals C having a powder X-ray diffraction spectrum having characteristics peaks at 2.theta.=12.6.degree., 13.7.degree., 15.4.degree., 18.1.degree., 19.0.degree., 20.6.degree., 23.5.degree. and 26.4.degree..

2. Anhydrous Aripiprazole Crystals C having a particular infrared absorption bands at 2939, 2804, 1680, 1375 and 780 cm.sup.-1 on the IR (Kbr) spectrum.

3. Anhydrous Aripiprazole Crystals C exhibiting an endothermic peak near about 150.2.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min).

4. Anhydrous Aripiprazole Crystals C having a solid .sup.13C-NMR spectrum having characteristic peaks at 32.8 ppm, 60.8 ppm, 74.9 ppm, 104.9 ppm, 152.2 ppm, 159.9 ppm, and 175.2 ppm.

5. A process for preparing Anhydrous Aripiprazole Crystals C having a powder X-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree., 13.7.degree., 15.4.degree., 18.1.degree., 19.0.degree., 20.6.degree., 23.5.degree., and 26.4.degree.; having particular infrared absorption bands at 2939, 2804, 1680, 1375, and 780 cm.sup.-1 on the IR (KBr) spectrum; exhibiting an endothermic peak near about 150.2.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); and having a solid .sup.13C-NMR spectrum having characteristic peaks at 32.8 ppm, 60.8 ppm, 74.9 ppm, 104.9 ppm, 152.2 ppm, 159.9 ppm, and 175.2 ppm, characterized by heating aripiprazole anhydrous crystals at a temperature higher than 140.degree. C. and lower than 150.degree. C.

6. A process for the preparation of granules, characterized by wet granulating Anhydrous Aripiprazole Crystals C having a powder X-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree., 13.7.degree., 15.4.degree., 18.1.degree., 19.0.degree., 20.6.degree., 23.5.degree., and 26.4.degree.; having particular infrared absorption bands at 2939, 2804, 1680, 1375, and 780 cm.sup.-1 on the IR (KBr) spectrum; exhibiting an endothermic peak near about 150.2.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); and having a solid .sup.13C-NMR spectrum having characteristic peaks at 32.8 ppm, 60.8 ppm, 74.9 ppm, 104.9 ppm, 152.2 ppm, 159.9 ppm, and 175.2 ppm, drying the obtained granules at 70 to 100.degree. C. and sizing it, then drying the sized granules at 70 to 100.degree. C. again.

7. A process for a pharmaceutical solid oral preparation, characterized by drying a pharmaceutical solid oral preparation comprising Anhydrous Aripiprazole Crystals C having a powder X-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree., 13.7.degree., 15.4.degree., 18.1.degree., 19.0.degree., 20.6.degree., 23.5.degree., and 26.4.degree.; having particular infrared absorption bands at 2939, 2804, 1680, 1375, and 780 cm.sup.-1 on the IR (KBr) spectrum; exhibiting an endothermic peak near about 150.2.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); and having a solid .sup.13C-NMR spectrum having characteristic peaks at 32.8 ppm, 60.8 ppm, 74.9 ppm, 104.9 ppm, 152.2 ppm, 159.9 ppm, and 175.2 ppm, and one or more pharmaceutically acceptable carriers at 70 to 100.degree. C.

8. A pharmaceutical solid oral preparation comprising Anhydrous Aripiprazole Crystals C having a powder X-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree., 13.7.degree., 15.4.degree., 18.1.degree., 19.0.degree., 20.6.degree., 23.5.degree., and 26.4.degree.; having particular infrared absorption bands at 2939, 2804, 1680, 1375, and 780 cm.sup.-1 on the IR (KBr) spectrum; exhibiting an endothermic peak near about 150.2.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); and having a solid .sup.13C-NMR spectrum having characteristic peaks at 32.8 ppm, 60.8 ppm, 74.9 ppm, 104.9 ppm, 152.2 ppm, 159.9 ppm, and 175.2 ppm, and one or more pharmaceutically acceptable carriers, wherein said pharmaceutical solid oral preparation has at least one dissolution rate selected from the group consisting 60% or more at pH 4.5 after 30 minutes, 70% or more at pH 4.5 after 60 minutes, and 55% or more at pH 5.0 after 60 minutes.

9. Anhydrous Aripiprazole Crystals C having a powder X-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree., 13.7.degree., 15.4.degree., 18.1.degree., 19.0.degree., 20.6.degree., 23.5.degree., and 26.4.degree.; having particular infrared absorption bands at 2939, 2804, 1680, 1375, and 780 cm.sup.-1 on the IR (KBr) spectrum; exhibiting an endothermic peak near about 150.2.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); and having a solid .sup.13C-NMR spectrum having characteristic peaks at 32.8 ppm, 60.8 ppm, 74.9 ppm, 104.9 ppm, 152.2 ppm, 159.9 ppm, and 175.2 ppm.

10. A pharmaceutical composition comprising Anhydrous Aripiprazole Crystals C having a powder x-ray diffraction spectrum having characteristic peaks at 2.theta.=12.6.degree., 13.7.degree., 15.4.degree., 18.1.degree., 19.0.degree., 20.6.degree., 23.5.degree., and 26.4.degree.; having particular infrared absorption bands at 2939, 2804, 1680, 1375, and 780 cm.sup.-1 on the IR (KBr) spectrum; exhibiting an endothermic peak near about 150.2.degree. C. in thermogravimetric/differential thermal analysis (heating rate 5.degree. C./min); and having a solid .sup.13C-NMR spectrum having characteristic peaks at 32.8 ppm, 60.8 ppm, 74.9 ppm, 104.9 ppm, 152.2 ppm, 159.9 ppm, and 175.2 ppm; together with a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc